Home > Press Releases > Targeted Protein Degraders Market

Targeted Protein Degraders Market Likely to Surpass USD 6.4 Billion by 2035

Report Code: HC-61242  |  Published in: Aug 2026, By MarketGenics  |  Number of pages: 263
Get PDF
Buy

Global Targeted Protein Degraders Market Forecast 2035:

According to the report, the global targeted protein degraders market is projected to expand from USD 0.4 billion in 2025 to USD 6.4 billion by 2035, registering a CAGR of 31.9%, the highest during the forecast period. Growth in the global targeted protein degraders market is supported by expanding applications across oncology and inflammatory diseases and increasing pharmaceutical investment.

Advances in molecular-glue and PROTAC platforms, alongside growing strategic collaborations, are further accelerating innovation and broadening therapeutic applications. For instance, in June 2025, Gilead Sciences and Kymera Therapeutics entered an agreement to develop oral molecular-glue CDK2 degraders, demonstrating increasing industry commitment to next-generation degradation technologies.

Additionally, industry data from BIO highlights strong biotechnology partnering activity, with 66,308 partnering meetings recorded at its 2025 convention, supporting collaboration-driven innovation and commercialization. Rising R&D investment, strategic partnerships, and technology diversification are accelerating TPD pipeline development and expanding commercial opportunities.              

Key Driver, Restraint, and Growth Opportunity Shaping the Global Targeted Protein Degraders Market

The expansion into extracellular and membrane protein degradation is driving market growth for targeted protein degraders by expanding target accessibility beyond intracellular proteins, allowing for selective degradation of previously difficult-to-drug proteins, and opening up new therapeutic opportunities in oncology, immunology, and other disease areas.                                               

TPD development remains challenging because degradation outcomes depend on target biology, E3-ligase recruitment, molecular architecture, cellular context, selectivity, and pharmacokinetics. These interdependent factors can make efficacy, safety, and drug exposure difficult to predict, increasing development complexity and potentially extending preclinical and clinical timelines.                     

AI-enabled platforms offer opportunities to improve target selection, degrader design, E3-ligase matching, and experimental prioritization. Emerging computational approaches are demonstrating improved prediction of protein degradability, enabling developers to reduce screening requirements and potentially accelerate identification of differentiated TPD candidates.             

Expansion of Global Targeted Protein Degraders Market

Increasing Adoption of Extracellular and Lysosomal Degradation Approaches

  • The targeted protein degraders market is growing due to the growing use of extracellular and lysosomal degradation techniques, which may target membrane-bound and secreted proteins in addition to intracellular ones. LYTAC platforms leverage lysosomal trafficking receptors to eliminate previously difficult-to-drug targets, broadening therapeutic opportunities across oncology, immunology, and other disease areas.
  • For instance, in 2025, Frontier Medicines demonstrated its DCAF2 E3 ligase platform can support targeted protein degradation, reinforcing expansion of degradation technologies beyond conventional intracellular targets and broadening opportunities for next-generation TPD applications.
  • Broader extracellular and lysosomal degradation capabilities expand the addressable target landscape, supporting innovation, therapeutic diversification, and long-term growth of the targeted protein degraders market.                                 

Regional Analysis of Global Targeted Protein Degraders Market

  • North America commands the highest demand for targeted protein degraders due to its advanced biotechnology ecosystem, substantial pharmaceutical R&D expenditure, sophisticated clinical infrastructure, and strong investment environment. For instance, Arvinas reinforces this leadership through its first FDA-approved PROTAC and expanding oncology and neurology pipeline, demonstrating strong regional clinical and commercial validation of TPD technologies. Advanced R&D capabilities, clinical validation, and pharmaceutical investment reinforce North America’s market leadership.
  • Asia Pacific is experiencing accelerated growth due to increasing biopharmaceutical investments, expanding clinical-development capabilities, strengthening precision-medicine infrastructure, and rising research activity in advanced drug-discovery technologies. Japan, China, South Korea, India, and Australia are progressively expanding TPD research, strategic collaborations, and development programs, supporting regional commercialization opportunities.           

Prominent players operating in the global targeted protein degraders market is Amphista Therapeutics Limited, Arvinas, Inc., BioTheryX, Inc., Bristol-Myers Squibb Company, C4 Therapeutics, Inc., Captor Therapeutics S.A., Cullgen Inc., Foghorn Therapeutics Inc., Frontier Medicines Corporation, Kymera Therapeutics, Inc., Monte Rosa Therapeutics, Inc., Nurix Therapeutics, Inc., Plexium, Inc., Triana Biomedicines, Other key players.      

The global targeted protein degraders market has been segmented as follows:

Global Targeted Protein Degraders Market Analysis, By Modality

  • Proteolysis Targeting Chimeras
  • Molecular Glue Degraders
  • Lysosome-Targeting Chimeras
  • Autophagy-Targeting Chimeras
  • Autophagosome-Tethering Compounds
  • Ribonuclease-Targeting Chimeras
  • Deubiquitinase-Targeting Chimeras
  • Hydrophobic Tagging
  • Other Targeted Protein Degrader Platforms

Global Targeted Protein Degraders Market Analysis, By Target Protein Class

  • Kinases
  • Transcription Factors
  • Nuclear Receptors
  • Epigenetic Regulators
  • Cell Cycle Proteins
  • Immune Signaling Proteins
  • DNA Repair Proteins
  • Other Intracellular Proteins

Global Targeted Protein Degraders Market Analysis, By Therapeutic Area

  • Oncology
    • Breast Cancer
    • Hematologic Malignancies
    • Solid Tumors
    • Others
  • Immunological & Inflammatory Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Respiratory Disorders
  • Ophthalmology
  • Rare & Genetic Diseases
  • Others  

Global Targeted Protein Degraders Market Analysis, By Stage of Development

  • Discovery Stage
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Commercialized

Global Targeted Protein Degraders Market Analysis, By Formulation

  • Oral Formulations
  • Injectable Formulations
  • Others

Global Targeted Protein Degraders Market Analysis, By Degradation Pathway

  • Ubiquitin-Proteasome System (UPS)
  • Autophagy-Lysosome Pathway

Global Targeted Protein Degraders Market Analysis, By Application

  • Drug Discovery
  • Target Identification & Validation
  • Therapeutics/Therapy Development
  • Research Use

Global Targeted Protein Degraders Market Analysis, By End-users

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutes
  • Hospitals & Cancer Centers
  • Diagnostic & Precision Medicine Companies
  • Other End-users

Global Targeted Protein Degraders Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Targeted Protein Degraders Market Outlook
      • 2.1.1. Targeted Protein Degraders Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising demand for therapies targeting previously undruggable proteins
        • 4.1.1.2. Growing clinical validation of PROTACs and molecular glues
        • 4.1.1.3. Advancements in degrader design and AI-enabled drug discovery
      • 4.1.2. Restraints
        • 4.1.2.1. Poor solubility, permeability, and oral bioavailability of degraders
        • 4.1.2.2. Complex ternary-complex formation limits degradation consistency
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Ecosystem Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Targeted Protein Degraders Market Demand
      • 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Targeted Protein Degraders Market Analysis, by Modality
    • 6.1. Key Segment Analysis
    • 6.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by Modality, 2021-2035
      • 6.2.1. Proteolysis Targeting Chimeras
      • 6.2.2. Molecular Glue Degraders
      • 6.2.3. Lysosome-Targeting Chimeras
      • 6.2.4. Autophagy-Targeting Chimeras
      • 6.2.5. Autophagosome-Tethering Compounds
      • 6.2.6. Ribonuclease-Targeting Chimeras
      • 6.2.7. Deubiquitinase-Targeting Chimeras
      • 6.2.8. Hydrophobic Tagging
      • 6.2.9. Other Targeted Protein Degrader Platforms
  • 7. Global Targeted Protein Degraders Market Analysis, by Target Protein Class
    • 7.1. Key Segment Analysis
    • 7.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by Target Protein Class, 2021-2035
      • 7.2.1. Kinases
      • 7.2.2. Transcription Factors
      • 7.2.3. Nuclear Receptors
      • 7.2.4. Epigenetic Regulators
      • 7.2.5. Cell Cycle Proteins
      • 7.2.6. Immune Signaling Proteins
      • 7.2.7. DNA Repair Proteins
      • 7.2.8. Other Intracellular Proteins
  • 8. Global Targeted Protein Degraders Market Analysis, by Therapeutic Area
    • 8.1. Key Segment Analysis
    • 8.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
      • 8.2.1. Oncology
        • 8.2.1.1. Breast Cancer
        • 8.2.1.2. Hematologic Malignancies
        • 8.2.1.3. Solid Tumors
        • 8.2.1.4. Others
      • 8.2.2. Immunological & Inflammatory Disorders
      • 8.2.3. Neurodegenerative Disorders
      • 8.2.4. Infectious Diseases
      • 8.2.5. Metabolic Disorders
      • 8.2.6. Respiratory Disorders
      • 8.2.7. Ophthalmology
      • 8.2.8. Rare & Genetic Diseases
      • 8.2.9. Others
  • 9. Global Targeted Protein Degraders Market Analysis, by Stage of Development
    • 9.1. Key Segment Analysis
    • 9.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by Stage of Development, 2021-2035
      • 9.2.1. Discovery Stage
      • 9.2.2. Preclinical
      • 9.2.3. Phase I
      • 9.2.4. Phase II
      • 9.2.5. Phase III
      • 9.2.6. Commercialized
  • 10. Global Targeted Protein Degraders Market Analysis, by Formulation
    • 10.1. Key Segment Analysis
    • 10.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by Formulation, 2021-2035
      • 10.2.1. Oral Formulations
      • 10.2.2. Injectable Formulations
      • 10.2.3. Others
  • 11. Global Targeted Protein Degraders Market Analysis, by Degradation Pathway
    • 11.1. Key Segment Analysis
    • 11.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by Degradation Pathway, 2021-2035
      • 11.2.1. Ubiquitin-Proteasome System (UPS)
      • 11.2.2. Autophagy-Lysosome Pathway
  • 12. Global Targeted Protein Degraders Market Analysis, by Application
    • 12.1. Key Segment Analysis
    • 12.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
      • 12.2.1. Drug Discovery
      • 12.2.2. Target Identification & Validation
      • 12.2.3. Therapeutics/Therapy Development
      • 12.2.4. Research Use
  • 13. Global Targeted Protein Degraders Market Analysis, by End-users
    • 13.1. Key Segment Analysis
    • 13.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-users, 2021-2035
      • 13.2.1. Pharmaceutical Companies
      • 13.2.2. Biotechnology Companies
      • 13.2.3. Contract Research Organizations
      • 13.2.4. Academic & Research Institutes
      • 13.2.5. Hospitals & Cancer Centers
      • 13.2.6. Diagnostic & Precision Medicine Companies
      • 13.2.7. Other End-users
  • 14. Global Targeted Protein Degraders Market Analysis, by Region
    • 14.1. Key Findings
    • 14.2. Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 14.2.1. North America
      • 14.2.2. Europe
      • 14.2.3. Asia Pacific
      • 14.2.4. Middle East
      • 14.2.5. Africa
      • 14.2.6. South America
  • 15. North America Targeted Protein Degraders Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. North America Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Modality
      • 15.3.2. Target Protein Class
      • 15.3.3. Therapeutic Area
      • 15.3.4. Stage of Development
      • 15.3.5. Formulation
      • 15.3.6. Degradation Pathway
      • 15.3.7. Application
      • 15.3.8. End-users
      • 15.3.9. Country
        • 15.3.9.1. USA
        • 15.3.9.2. Canada
        • 15.3.9.3. Mexico
    • 15.4. USA Targeted Protein Degraders Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Modality
      • 15.4.3. Target Protein Class
      • 15.4.4. Therapeutic Area
      • 15.4.5. Stage of Development
      • 15.4.6. Formulation
      • 15.4.7. Degradation Pathway
      • 15.4.8. Application
      • 15.4.9. End-users
    • 15.5. Canada Targeted Protein Degraders Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Modality
      • 15.5.3. Target Protein Class
      • 15.5.4. Therapeutic Area
      • 15.5.5. Stage of Development
      • 15.5.6. Formulation
      • 15.5.7. Degradation Pathway
      • 15.5.8. Application
      • 15.5.9. End-users
    • 15.6. Mexico Targeted Protein Degraders Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Modality
      • 15.6.3. Target Protein Class
      • 15.6.4. Therapeutic Area
      • 15.6.5. Stage of Development
      • 15.6.6. Formulation
      • 15.6.7. Degradation Pathway
      • 15.6.8. Application
      • 15.6.9. End-users
  • 16. Europe Targeted Protein Degraders Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Europe Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Modality
      • 16.3.2. Target Protein Class
      • 16.3.3. Therapeutic Area
      • 16.3.4. Stage of Development
      • 16.3.5. Formulation
      • 16.3.6. Degradation Pathway
      • 16.3.7. Application
      • 16.3.8. End-users
      • 16.3.9. Country
        • 16.3.9.1. Germany
        • 16.3.9.2. United Kingdom
        • 16.3.9.3. France
        • 16.3.9.4. Italy
        • 16.3.9.5. Spain
        • 16.3.9.6. Netherlands
        • 16.3.9.7. Nordic Countries
        • 16.3.9.8. Poland
        • 16.3.9.9. Russia & CIS
        • 16.3.9.10. Rest of Europe
    • 16.4. Germany Targeted Protein Degraders Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Modality
      • 16.4.3. Target Protein Class
      • 16.4.4. Therapeutic Area
      • 16.4.5. Stage of Development
      • 16.4.6. Formulation
      • 16.4.7. Degradation Pathway
      • 16.4.8. Application
      • 16.4.9. End-users
    • 16.5. United Kingdom Targeted Protein Degraders Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Modality
      • 16.5.3. Target Protein Class
      • 16.5.4. Therapeutic Area
      • 16.5.5. Stage of Development
      • 16.5.6. Formulation
      • 16.5.7. Degradation Pathway
      • 16.5.8. Application
      • 16.5.9. End-users
    • 16.6. France Targeted Protein Degraders Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Modality
      • 16.6.3. Target Protein Class
      • 16.6.4. Therapeutic Area
      • 16.6.5. Stage of Development
      • 16.6.6. Formulation
      • 16.6.7. Degradation Pathway
      • 16.6.8. Application
      • 16.6.9. End-users
    • 16.7. Italy Targeted Protein Degraders Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Modality
      • 16.7.3. Target Protein Class
      • 16.7.4. Therapeutic Area
      • 16.7.5. Stage of Development
      • 16.7.6. Formulation
      • 16.7.7. Degradation Pathway
      • 16.7.8. Application
      • 16.7.9. End-users
    • 16.8. Spain Targeted Protein Degraders Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Modality
      • 16.8.3. Target Protein Class
      • 16.8.4. Therapeutic Area
      • 16.8.5. Stage of Development
      • 16.8.6. Formulation
      • 16.8.7. Degradation Pathway
      • 16.8.8. Application
      • 16.8.9. End-users
    • 16.9. Netherlands Targeted Protein Degraders Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Modality
      • 16.9.3. Target Protein Class
      • 16.9.4. Therapeutic Area
      • 16.9.5. Stage of Development
      • 16.9.6. Formulation
      • 16.9.7. Degradation Pathway
      • 16.9.8. Application
      • 16.9.9. End-users
    • 16.10. Nordic Countries Targeted Protein Degraders Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Modality
      • 16.10.3. Target Protein Class
      • 16.10.4. Therapeutic Area
      • 16.10.5. Stage of Development
      • 16.10.6. Formulation
      • 16.10.7. Degradation Pathway
      • 16.10.8. Application
      • 16.10.9. End-users
    • 16.11. Poland Targeted Protein Degraders Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Modality
      • 16.11.3. Target Protein Class
      • 16.11.4. Therapeutic Area
      • 16.11.5. Stage of Development
      • 16.11.6. Formulation
      • 16.11.7. Degradation Pathway
      • 16.11.8. Application
      • 16.11.9. End-users
    • 16.12. Russia & CIS Targeted Protein Degraders Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Modality
      • 16.12.3. Target Protein Class
      • 16.12.4. Therapeutic Area
      • 16.12.5. Stage of Development
      • 16.12.6. Formulation
      • 16.12.7. Degradation Pathway
      • 16.12.8. Application
      • 16.12.9. End-users
    • 16.13. Rest of Europe Targeted Protein Degraders Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Modality
      • 16.13.3. Target Protein Class
      • 16.13.4. Therapeutic Area
      • 16.13.5. Stage of Development
      • 16.13.6. Formulation
      • 16.13.7. Degradation Pathway
      • 16.13.8. Application
      • 16.13.9. End-users
  • 17. Asia Pacific Targeted Protein Degraders Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Asia Pacific Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Modality
      • 17.3.2. Target Protein Class
      • 17.3.3. Therapeutic Area
      • 17.3.4. Stage of Development
      • 17.3.5. Formulation
      • 17.3.6. Degradation Pathway
      • 17.3.7. Application
      • 17.3.8. End-users
      • 17.3.9. Country
        • 17.3.9.1. China
        • 17.3.9.2. India
        • 17.3.9.3. Japan
        • 17.3.9.4. South Korea
        • 17.3.9.5. Australia and New Zealand
        • 17.3.9.6. Indonesia
        • 17.3.9.7. Malaysia
        • 17.3.9.8. Thailand
        • 17.3.9.9. Vietnam
        • 17.3.9.10. Rest of Asia Pacific
    • 17.4. China Targeted Protein Degraders Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Modality
      • 17.4.3. Target Protein Class
      • 17.4.4. Therapeutic Area
      • 17.4.5. Stage of Development
      • 17.4.6. Formulation
      • 17.4.7. Degradation Pathway
      • 17.4.8. Application
      • 17.4.9. End-users
    • 17.5. India Targeted Protein Degraders Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Modality
      • 17.5.3. Target Protein Class
      • 17.5.4. Therapeutic Area
      • 17.5.5. Stage of Development
      • 17.5.6. Formulation
      • 17.5.7. Degradation Pathway
      • 17.5.8. Application
      • 17.5.9. End-users
    • 17.6. Japan Targeted Protein Degraders Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Modality
      • 17.6.3. Target Protein Class
      • 17.6.4. Therapeutic Area
      • 17.6.5. Stage of Development
      • 17.6.6. Formulation
      • 17.6.7. Degradation Pathway
      • 17.6.8. Application
      • 17.6.9. End-users
    • 17.7. South Korea Targeted Protein Degraders Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Modality
      • 17.7.3. Target Protein Class
      • 17.7.4. Therapeutic Area
      • 17.7.5. Stage of Development
      • 17.7.6. Formulation
      • 17.7.7. Degradation Pathway
      • 17.7.8. Application
      • 17.7.9. End-users
    • 17.8. Australia and New Zealand Targeted Protein Degraders Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Modality
      • 17.8.3. Target Protein Class
      • 17.8.4. Therapeutic Area
      • 17.8.5. Stage of Development
      • 17.8.6. Formulation
      • 17.8.7. Degradation Pathway
      • 17.8.8. Application
      • 17.8.9. End-users
    • 17.9. Indonesia Targeted Protein Degraders Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Modality
      • 17.9.3. Target Protein Class
      • 17.9.4. Therapeutic Area
      • 17.9.5. Stage of Development
      • 17.9.6. Formulation
      • 17.9.7. Degradation Pathway
      • 17.9.8. Application
      • 17.9.9. End-users
    • 17.10. Malaysia Targeted Protein Degraders Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Modality
      • 17.10.3. Target Protein Class
      • 17.10.4. Therapeutic Area
      • 17.10.5. Stage of Development
      • 17.10.6. Formulation
      • 17.10.7. Degradation Pathway
      • 17.10.8. Application
      • 17.10.9. End-users
    • 17.11. Thailand Targeted Protein Degraders Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Modality
      • 17.11.3. Target Protein Class
      • 17.11.4. Therapeutic Area
      • 17.11.5. Stage of Development
      • 17.11.6. Formulation
      • 17.11.7. Degradation Pathway
      • 17.11.8. Application
      • 17.11.9. End-users
    • 17.12. Vietnam Targeted Protein Degraders Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Modality
      • 17.12.3. Target Protein Class
      • 17.12.4. Therapeutic Area
      • 17.12.5. Stage of Development
      • 17.12.6. Formulation
      • 17.12.7. Degradation Pathway
      • 17.12.8. Application
      • 17.12.9. End-users
    • 17.13. Rest of Asia Pacific Targeted Protein Degraders Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Modality
      • 17.13.3. Target Protein Class
      • 17.13.4. Therapeutic Area
      • 17.13.5. Stage of Development
      • 17.13.6. Formulation
      • 17.13.7. Degradation Pathway
      • 17.13.8. Application
      • 17.13.9. End-users
  • 18. Middle East Targeted Protein Degraders Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Middle East Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Modality
      • 18.3.2. Target Protein Class
      • 18.3.3. Therapeutic Area
      • 18.3.4. Stage of Development
      • 18.3.5. Formulation
      • 18.3.6. Degradation Pathway
      • 18.3.7. Application
      • 18.3.8. End-users
      • 18.3.9. Country
        • 18.3.9.1. Turkey
        • 18.3.9.2. UAE
        • 18.3.9.3. Saudi Arabia
        • 18.3.9.4. Israel
        • 18.3.9.5. Rest of Middle East
    • 18.4. Turkey Targeted Protein Degraders Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Modality
      • 18.4.3. Target Protein Class
      • 18.4.4. Therapeutic Area
      • 18.4.5. Stage of Development
      • 18.4.6. Formulation
      • 18.4.7. Degradation Pathway
      • 18.4.8. Application
      • 18.4.9. End-users
    • 18.5. UAE Targeted Protein Degraders Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Modality
      • 18.5.3. Target Protein Class
      • 18.5.4. Therapeutic Area
      • 18.5.5. Stage of Development
      • 18.5.6. Formulation
      • 18.5.7. Degradation Pathway
      • 18.5.8. Application
      • 18.5.9. End-users
    • 18.6. Saudi Arabia Targeted Protein Degraders Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Modality
      • 18.6.3. Target Protein Class
      • 18.6.4. Therapeutic Area
      • 18.6.5. Stage of Development
      • 18.6.6. Formulation
      • 18.6.7. Degradation Pathway
      • 18.6.8. Application
      • 18.6.9. End-users
    • 18.7. Israel Targeted Protein Degraders Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Modality
      • 18.7.3. Target Protein Class
      • 18.7.4. Therapeutic Area
      • 18.7.5. Stage of Development
      • 18.7.6. Formulation
      • 18.7.7. Degradation Pathway
      • 18.7.8. Application
      • 18.7.9. End-users
    • 18.8. Rest of Middle East Targeted Protein Degraders Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Modality
      • 18.8.3. Target Protein Class
      • 18.8.4. Therapeutic Area
      • 18.8.5. Stage of Development
      • 18.8.6. Formulation
      • 18.8.7. Degradation Pathway
      • 18.8.8. Application
      • 18.8.9. End-users
  • 19. Africa Targeted Protein Degraders Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Africa Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Modality
      • 19.3.2. Target Protein Class
      • 19.3.3. Therapeutic Area
      • 19.3.4. Stage of Development
      • 19.3.5. Formulation
      • 19.3.6. Degradation Pathway
      • 19.3.7. Application
      • 19.3.8. End-users
      • 19.3.9. Country
        • 19.3.9.1. South Africa
        • 19.3.9.2. Egypt
        • 19.3.9.3. Nigeria
        • 19.3.9.4. Algeria
        • 19.3.9.5. Rest of Africa
    • 19.4. South Africa Targeted Protein Degraders Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Modality
      • 19.4.3. Target Protein Class
      • 19.4.4. Therapeutic Area
      • 19.4.5. Stage of Development
      • 19.4.6. Formulation
      • 19.4.7. Degradation Pathway
      • 19.4.8. Application
      • 19.4.9. End-users
    • 19.5. Egypt Targeted Protein Degraders Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Modality
      • 19.5.3. Target Protein Class
      • 19.5.4. Therapeutic Area
      • 19.5.5. Stage of Development
      • 19.5.6. Formulation
      • 19.5.7. Degradation Pathway
      • 19.5.8. Application
      • 19.5.9. End-users
    • 19.6. Nigeria Targeted Protein Degraders Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Modality
      • 19.6.3. Target Protein Class
      • 19.6.4. Therapeutic Area
      • 19.6.5. Stage of Development
      • 19.6.6. Formulation
      • 19.6.7. Degradation Pathway
      • 19.6.8. Application
      • 19.6.9. End-users
    • 19.7. Algeria Targeted Protein Degraders Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Modality
      • 19.7.3. Target Protein Class
      • 19.7.4. Therapeutic Area
      • 19.7.5. Stage of Development
      • 19.7.6. Formulation
      • 19.7.7. Degradation Pathway
      • 19.7.8. Application
      • 19.7.9. End-users
    • 19.8. Rest of Africa Targeted Protein Degraders Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Modality
      • 19.8.3. Target Protein Class
      • 19.8.4. Therapeutic Area
      • 19.8.5. Stage of Development
      • 19.8.6. Formulation
      • 19.8.7. Degradation Pathway
      • 19.8.8. Application
      • 19.8.9. End-users
  • 20. South America Targeted Protein Degraders Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. South America Targeted Protein Degraders Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Modality
      • 20.3.2. Target Protein Class
      • 20.3.3. Therapeutic Area
      • 20.3.4. Stage of Development
      • 20.3.5. Formulation
      • 20.3.6. Degradation Pathway
      • 20.3.7. Application
      • 20.3.8. End-users
      • 20.3.9. Country
        • 20.3.9.1. Brazil
        • 20.3.9.2. Argentina
        • 20.3.9.3. Rest of South America
    • 20.4. Brazil Targeted Protein Degraders Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Modality
      • 20.4.3. Target Protein Class
      • 20.4.4. Therapeutic Area
      • 20.4.5. Stage of Development
      • 20.4.6. Formulation
      • 20.4.7. Degradation Pathway
      • 20.4.8. Application
      • 20.4.9. End-users
    • 20.5. Argentina Targeted Protein Degraders Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Modality
      • 20.5.3. Target Protein Class
      • 20.5.4. Therapeutic Area
      • 20.5.5. Stage of Development
      • 20.5.6. Formulation
      • 20.5.7. Degradation Pathway
      • 20.5.8. Application
      • 20.5.9. End-users
    • 20.6. Rest of South America Targeted Protein Degraders Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Modality
      • 20.6.3. Target Protein Class
      • 20.6.4. Therapeutic Area
      • 20.6.5. Stage of Development
      • 20.6.6. Formulation
      • 20.6.7. Degradation Pathway
      • 20.6.8. Application
      • 20.6.9. End-users
  • 21. Key Players/ Company Profile
    • 21.1. Amphista Therapeutics Limited
      • 21.1.1. Company Details/ Overview
      • 21.1.2. Company Financials
      • 21.1.3. Key Customers and Competitors
      • 21.1.4. Business/ Industry Portfolio
      • 21.1.5. Product Portfolio/ Specification Details
      • 21.1.6. Pricing Data
      • 21.1.7. Strategic Overview
      • 21.1.8. Recent Developments
    • 21.2. Arvinas, Inc.
    • 21.3. BioTheryX, Inc.
    • 21.4. Bristol-Myers Squibb Company
    • 21.5. C4 Therapeutics, Inc.
    • 21.6. Captor Therapeutics S.A.
    • 21.7. Cullgen Inc.
    • 21.8. Foghorn Therapeutics Inc.
    • 21.9. Frontier Medicines Corporation
    • 21.10. Kymera Therapeutics, Inc.
    • 21.11. Monte Rosa Therapeutics, Inc.
    • 21.12. Nurix Therapeutics, Inc.
    • 21.13. Plexium, Inc.
    • 21.14. Triana Biomedicines
    • 21.15. Others

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation